https://orcid.org/0000-0002-6899-2478
References
- Ozturk S, Turgutalp K, Arici M, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant. 2020;35(12):2083–2095. doi:10.1093/ndt/gfaa271
- Torres R, Toro L, Sanhueza ME, et al. Clinical efficacy of SARS-CoV-2 vaccination in hemodialysis patients. Kidney Int Rep. 2022;7(10):2176–2185. doi:10.1016/j.ekir.2022.07.007
- Anand S, Montez-Rath ME, Han J, et al. SARS-CoV-2 vaccine antibody response and breakthrough infection in patients receiving dialysis. Ann Intern Med. 2022;175(3):371–378. doi:10.7326/M21-4176
- Quiroga B, Soler MJ, Ortiz A, et al. Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study. Nephrol Dial Transplant. 2023;38(4):969–981. doi:10.1093/ndt/gfac307
- Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol. 2019;23(4):437–447. doi:10.1007/s10157-018-1641-8
- Hirai K, Shimotashiro M, Sonoda T, Okumura T, Ookawara S, Morishita Y. Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients. Clin Exp Nephrol. 2022;26(9):925–932. doi:10.1007/s10157-022-02223-y
- Hirai K, Shimotashiro M, Okumura T, Ookawara S, Morishita Y. Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients. Kidney Res Clin Pract. 2024. doi:10.23876/j.krcp.23.121
- Cheng CC, Platen L, Christa C, et al. Improved SARS-CoV-2 neutralization of delta and Omicron BA.1 variants of concern after fourth vaccination in hemodialysis patients. Vaccines. 2022;10(8):1328. doi:10.3390/vaccines10081328
- Housset P, Kubab S, Hanafi L, et al. Humoral response after a fourth ”booster” dose of a Coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients. Kidney Int. 2022;101(6):1289–1290. doi:10.1016/j.kint.2022.04.006
- Einbinder Y, Perl J, Nacasch N, et al. Humoral response and SARS-CoV-2 infection risk following the third and fourth doses of the BNT162b2 vaccine in dialysis patients. Am J Nephrol. 2022;53(7):586–590. doi:10.1159/000525309
- Becker M, Cossmann A, Lurken K, et al. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients. Front Immunol. 2022;13:1004045. doi:10.3389/fimmu.2022.1004045
- Kanai D, Wakui H, Hanaoka M, et al. Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis. Clin Exp Nephrol. 2023;27(7):1–9.
- Shinzato T, Nakai S, Fujita Y, et al. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron. 1994;67(3):280–290. doi:10.1159/000187980
- Bensouna I, Caudwell V, Kubab S, et al. SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am J Kidney Dis. 2022;79(2):185–92 e1. doi:10.1053/j.ajkd.2021.08.005
- Dekervel M, Henry N, Torreggiani M, et al. Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clin Kidney J. 2021;14(11):2349–2355. doi:10.1093/ckj/sfab152
- Agur T, Zingerman B, Ben-Dor N, et al. Humoral response to the third dose of BNT162b2 COVID-19 vaccine among hemodialysis patients. Nephron. 2022;147(3–4):1–8.
- Miao M, Wu M, Li Y, et al. Clinical potential of hypoxia inducible factors prolyl hydroxylase inhibitors in treating nonanemic diseases. Front Pharmacol. 2022;13:837249. doi:10.3389/fphar.2022.837249
- Jellusova J, Cato MH, Apgar JR, et al. Gsk3 is a metabolic checkpoint regulator in B cells. Nat Immunol. 2017;18(3):303–312. doi:10.1038/ni.3664